Unraveling the drug resistance web in IBD: The gut microbiota-immunity-epigenetics axis
Qing Li, Mingrong Cheng, Xiaoyue Wang, Weiwei Li, Feng Zhang · 2026
Read Unraveling the drug resistance web in IBD: The gut microbiota-immunity-epigenetics axis by Qing Li, Mingrong Cheng, Xiaoyue Wang, Weiwei Li, Feng Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13540173.txt.
Description
Qing Li, Mingrong Cheng, Xiaoyue Wang, Weiwei Li, and Feng Zhang published a 2026 review on why drugs stop working in inflammatory bowel disease, or IBD. Resistance to modern precision treatments is a major barrier for patients. Older studies usually blamed a single molecule or pathway.
The authors describe a web of three interacting systems: the gut microbiota, the immune system, and epigenetics, the chemical marks that control gene activity. They review resistance to key medicines, including anti-TNF biologics, vedolizumab, and JAK inhibitors. Their model casts disturbed gut microbes as the initiator, immune disorder as the amplifier, and epigenetic change as a third loop. Seeing resistance as a system may reveal new ways to restore drug response.
Catalog record
| CREATOR | Qing Li, Mingrong Cheng, Xiaoyue Wang, Weiwei Li, Feng Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 94 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |